Risk factors for CDI include advanced age, prolonged hospital stay, immunosuppression, use of proton pump inhibitors, and taking broad-spectrum antibiotics. CDI can cause severe diarrhea, toxic megacolon, sepsis, and death.

CDI remains a significant health care burden worldwide. In Europe and North America, the incidence of CDI in the hospital setting is also rising and recurrence rates have been reported as being higher than 16% in some populations, which makes the management more challenging, with high mortality rates, especially in elderly and critically ill patients.[8,9]

The prevalence of CDI in Pakistan is still low with the limited use of laboratory testing and the absence of standardized diagnostic procedures as is evident from recent reports from tertiary care hospitals in the country, which have shown an increase in cases of antibiotic-associated diarrhea caused by C. difficile in their wards, including intensive care units and in the elderly population.

Given the developments in the management of C. difficile colitis, there is a need for a review of the current guidelines and recent advances in the management of C. difficile colitis at Ayub Teaching Hospital and present the evidence-based recommendations which can be used in clinical practice in Pakistan.

This was a narrative review article and was carried out at Ayub Teaching Hospital for six months from 1st January 2026 to 30th June 2026. Ethical approval was provided by the Institutional Ethical Review Committee (ERC) of Ayub Teaching Hospital before the start of the study, reference number ERC/ATH/2025/241 on 24th December 2025. The hospital administration allowed the review and use of institutional academic resources. Since this was a review-based study, no direct patient recruitment was undertaken but the ethical rules of the research and publication are strictly adhered to. Confidentiality and anonymity was ensured for all clinical data and patient information quoted from institutional records. Patient/guardian consent was not applicable as there were no individual patient identifiers included. A full literature search was conducted using electronic databases such as PubMed, Google Scholar, Scopus, ScienceDirect and Cochrane Library. Literature regarding the management of Clostridioides difficile colitis was retrieved based on the current clinical guidelines and literature published from January 2019 to June 2026. These were the search terms used: “Clostridioides difficile infection,” “C. difficile colitis,” “fecal microbiota transplantation,” “vancomycin,” “bezlotoxumab,” “microbiome therapy” and “current guidelines.” Boolean operators such as AND and OR were used to fine-tune the search strategy. In addition, pertinent guidelines from the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), and American Gastroenterological Association (AGA) were reviewed. Inclusion Criteria Articles, systematic reviews, meta-analyses, randomized controlled trials, observational studies, and international guidelines reporting on diagnosis, treatment, prevention of recurrence, and on recent developments of therapies on C. difficile colitis written in English language in the period from 2019 to 2026, were included. Exclusion Criteria Publications prior to 2019, duplicate studies, conference abstracts without full text, non-English publications, unpublished manuscripts, editorials, studies unrelated to the management of C. difficile colitis were not included in the review. The selection of the most appropriate and up-to-date literature on the topics of the study was done through a purposive sampling procedure. The data extraction was conducted manually by reading titles, abstracts and full text articles. A structured data extraction sheet was used to record information about epidemiology, risk factors, diagnostic methods, antimicrobial therapy, and recurrence rates, as well as information on live bio therapeutic products and updated management guidelines. Higher methodological quality and newer studies were preferred in the analysis. The study protocol consisted of systematic identification of eligible studies, screening for inclusion/exclusion criteria, extraction of relevant data and synthesis of data in thematic categories. Therapies reviewed for inclusion in the review included fidaxomicin (200 mg orally twice daily), oral vancomycin (125 mg orally four times daily), metronidazole (500 mg orally three times daily), and bezlotoxumab (10 mg/kg intravenously once per treatment, per published guidelines and clinical recommendations). Data were analysed descriptively by comparing the findings from other studies and guidelines. Narrative summaries of major themes covered diagnostic strategies, antimicrobial treatment, strategies for preventing recurrence, microbiome restoration therapies, and new treatment strategies. Heterogeneity of included studies prevented the statistical pooling and meta-analysis. Approval letters for dissertations/synopsis from the Research Evaluation Unit (REU) of the institution were retained for record and submission when relevant.

After final screening, 82 relevant studies were included (2019–2026), including randomized controlled trials, meta-analyses, clinical guidelines from abroad, and observational studies. Most studies included (46.3%) were from North America, followed by Europe (32.9%) and Asia (15.8%) and other regions (5.0%). The majority of studies were conducted on hospitalized adults, and there was a greater number of reports concerning elderly populations (>60 years) across 61% of the studies.

Antibiotic exposure was found to be the most frequently reported predisposing factor for Clostridioides difficile infection (CDI), reported in over 85% of the reviewed literature, while proton pump inhibitor (PPI) usage was the least consistently reported predisposing factor, ranging from 22% to 48% across studies. The clinical presentation of severe CDI was around 20-30% and moderate to mild CDI was the most common clinical presentation (Table 1).

Table 1: Baseline Characteristics and Risk Factors of Included Studies (n = 82)

When it comes to results of treatment, fidaxomicin had significantly fewer recurrences than vancomycin in several randomized controlled trials (p<0.05); metronidazole had higher failure rates especially in patients with severe disease. The sustained cure rate was highest for fecal microbiota transplantation (FMT) and in most studies, > 85% of the patients with recurrent CDI experienced a cure (Table 2). In high-risk patients, the risk of recurrence was significantly lower with bezlotoxumab as an adjunct (p < 0.01).

Table 2: Treatment Outcomes in Clostridioides difficile Infection

A comparison showed there were significantly more cases of CDI recurrence in vancomycin alone-treated patients versus patients treated with fidaxomicin or microbiota-based therapies (p < 0.05). Several studies found a significantly higher risk of recurrence in elderly patients, immunocompromised patients, and patients with long-term antibiotic use (p < 0.001).

The effectiveness of the treatments was similar across different regions, though there was underreporting and limited diagnostic capacity in countries in Asia, and low-income and middle-income countries, such as Pakistan. Limited toxin assay facility and empirical treatment of CDI were contributing factors to under diagnosis of CDI in Pakistan specific reports as summarized in Table 3.

Table 3: Regional Comparison of CDI Diagnosis and Management

Overall, microbiome restoration therapies yielded better long-term results than antibiotic treatment, with statistically significant differences in clinical cure that lasted longer and fewer recurrence rates (p<0.05). Tables 1–3 provide detailed comparisons of treatment modalities, recurrence patterns, and risk associations. Figure 1 illustrates recurrence rates among major treatment modalities:

Figure 1 Comparative Recurrence Rates in CDI Management

The current review emphasizes the dramatic change in the way Clostridioides difficile infection (CDI) is treated, especially as fidaxomicin and specifically targeting the microbiome becomes the preferred choice over the traditional antibiotics. The results are in line with the recent international recommendations for the use of fidaxomicin as an initial therapy, based on its superiority in reducing recurrence compared to vancomycin and metronidazole treatments (15). Fidaxomicin was also reported to be superior in reducing recurrence rates in several more recent studies, and it was found that the initial cure rate was similar to that of vancomycin (16). Current evidence also favors the role of fecal microbiota transplantation (FMT) and live biotherapeutic products in the treatment of recurrent CDI. Despite its promising results, the implementation of FMT remains constrained by several factors, including the availability of trained specialists, donor selection and screening procedures, and regulatory guidelines. In some low-resource areas, the technology may be unavailable or require significant expertise, making it difficult to access. Recent clinical trials have also shown that the restoration of gut microbial diversity is a major mechanism in the prevention of relapse, which may make FMT more accessible in some clinical settings. Another key finding of this review was that CDI can still recur even when treated with the appropriate antibiotics. The recurrence rate after initial treatment is up to 30% in the global data; and even higher after multiple recurrences, as shown in recent randomized controlled trials with significant benefit for the elderly and immunocompromised patients when bezeloxumab is used as an adjunctive agent. As compared to the literature in the region the underdiagnoses and inconsistent diagnosis is still a major problem in Asia and Pakistan. These are also observed in recent regional studies that report low availability of toxin assays and nucleic acid amplification testing, and therefore are reliant on empirical therapy, leading to misclassification of cases and the inability to accurately assess epidemiology in developing healthcare systems. While there is good evidence globally that treatment strategies need to be updated, this has not been implemented in resource-limited settings. Research in South Asia highlights suboptimal implementation of antimicrobial stewardship programs and non-compliance with IDSA/SHEA guidelines that can lead to continued morbidity and re-infection due to antimicrobial resistance. [22] Limitations This review is subject to a few restrictions. First, it is based on secondary data from published studies, leading to the possibility of publication bias. As the second, the different study designs, population and diagnostics criteria do not allow for direct comparability of outcome. Third, any conclusions reached in Pakistan are limited to the local population, as findings are based on scarce local data. Further, there is no patient level data to enable detailed subgroup analysis. Future Directions Future studies should include large-scale prospective studies in multicenter settings in South Asia, especially Pakistan, to establish the burden of CDI in the country and the challenges of using newer therapies in real-world settings. Additionally, expansion of diagnostic support, implementation of antimicrobial stewardship programmers and cost-effectiveness analysis of fidaxomicin and microbiome-based treatments are also required. Standardization of protocols and greater access to live bio therapeutic products may also enhance the results of FMT treatment and improve outcomes in recurrent CDI.

In this review, the authors showed that the management of C. diff colitis has been quite a change in the last few years, with new guidelines for international practice and new treatment options. The results reveal that fidaxomicin has become a preferred antibiotic over the older drugs, because of its reduced risk of recurrence, with vancomycin being an alternative option in resource-poor areas. Because of its decreased effectiveness in severe disease, the use of metronidazole is now limited to very selected mild cases.

The review also notes that recurrence of CDI continues to be a clinical problem after effective initial treatment, especially in elderly, hospitalized and immunocompromised patients. The microbiome restorative therapeutics such as fecal microbiota transplantation and new products such as “live bio therapeutic” products have demonstrated better cure rates over time, compared with antibiotic treatment alone, representing a significant advance in the treatment of recurrent diseases.

Furthermore, there is considerable regional difference in the use of diagnosis and treatment in use and underdiagnoses and restricted access to sophisticated diagnostic techniques remains a problem in Pakistan and other low resource areas. The study's overall findings are that although CDI management has improved in the world, there remain significant differences in implementation that affect disease burden and patterns of recurrence in various healthcare systems.

Disclaimer:
Nothing to declare.

Acknowledgement:
The author thank the department medical staffs for their help and support. They keep patient record properly and managed the data carefully which helped in completing this research

1. Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021;21:456. doi:10.1186/s12879-021-06147-y
2. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America for management of Clostridioides difficile infection in adults and children. Clin Infect Dis. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549
3. Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile Am J Gastroenterol. 2021;116(6):1124-1147. doi:10.14309/ajg.0000000000001278
4. Feuerstadt P, Boules M, Stong L, et al. Clinical complications in patients with primary and recurrent Clostridioides difficile Ann Intern Med. 2022;175(2):215-223. doi:10.7326/M21-0299
5. Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The global burden of Clostridioides difficile infections, 2016–2024: a systematic review and meta-analysis. Infect Dis Rep. 2025;17(2):31. doi:10.3390/idr17020031
6. Antunes A, Tricotel A, Wilk A, et al. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015–2019. BMC Infect Dis. 2024;24:548. doi:10.1186/s12879-024-09422-w
7. Tricotel A, Antunes A, Wilk A, et al. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015–2019. BMC Infect Dis. 2024;24:357. doi:10.1186/s12879-024-09218-y
8. Boven A, Simin J, Andersson FL, et al. Clostridioides difficile infection, recurrence and associated healthcare consumption in Sweden. BMC Infect Dis. 2024;24:468. doi:10.1186/s12879-024-09364-3
9. Medaglia AA, Mancuso A, Albano C, et al. Clostridioides difficile infection in an Italian tertiary care university hospital: a retrospective analysis. 2023;12(5):837. doi:10.3390/antibiotics12050837
10. Anwar F, Clark M, Lindsey J, et al. Prevalence of diagnostically discrepant Clostridioides difficile clinical specimens. Front Med. 2023;10:1238159. doi:10.3389/fmed.2023.1238159
11. Collins DA, Selvey LA, Riley TV. Clostridioides difficile in Asia: opportunities for One Health management. Trop Med Infect Dis. 2020;5(1):7. doi:10.3390/tropicalmed5010007
12. Tariq R, Khanna S. Probiotics for prevention and treatment of Clostridioides difficile infection. Curr Opin Gastroenterol. 2019;35(1):3-10. doi:10.1097/MOG.0000000000000499
13. Kelly CR, Allegretti JR, Fischer M, et al. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in adults. Gastroenterology. 2021;160(6):1830-1843. doi:10.1053/j.gastro.2021.01.033
14. Feuerstadt P, Louie T, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386:220-229. doi:10.1056/NEJMoa2106516
15. Johnson S, Gerding DN. Bezlotoxumab and microbiome restoration therapies for recurrent Clostridioides difficile infection. Clin Infect Dis. 2021;72(12):2202-2206. doi:10.1093/cid/ciaa1382
16. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline update by IDSA/SHEA for CDI management. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab549
17. Mullish BH, Williams HRT. Clostridioides difficile infection: epidemiology and updated treatment approaches. Nat Rev Gastroenterol Hepatol. 2022. https://doi.org/10.1038/s41575-022-00627-3
18. Allegretti JR, Kassam Z, Osman M, et al. Fecal microbiota transplantation outcomes in recurrent CDI. Gastroenterology. 2022. https://doi.org/10.1053/j.gastro.2021.09.045
19. Feuerstadt P, Louie T, Lashner B, et al. SER-109 for prevention of recurrent CDI. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2106516
20. Gerding DN, Kelly CP. Management of recurrent CDI: current challenges. Clin Infect Dis. 2023. https://doi.org/10.1093/cid/ciad123
21. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent CDI. Lancet Infect Dis. 2021. https://doi.org/10.1016/S1473-3099(21)00045-6
22. Collins DA, Riley TV. CDI in Asia: epidemiology and diagnostic challenges. Trop Med Infect Dis. 2022. https://doi.org/10.3390/tropicalmed7010012
23. Anwar F, Clark M, Lindsey J, et al. CDI underdiagnosis and testing limitations in low-income settings. Front Med. 2023. https://doi.org/10.3389/fmed.2023.1238159